Strategic Focus & Partnerships

Our innovations in specialty care enable us to deliver the targeted medicines and novel, patient-friendly drug delivery systems that make a difference to patients, physicians and caregivers around the world.

Building Alliances for patient-centric Solutions

For us, partnering is a key element in delivering meaningful therapies to patients with unmet medical needs. To complement our company's own R&D efforts, we collaborate with strategic partners to source new compounds, gain access to the latest technology platforms, and develop novel therapeutics for patients.

Our goal is to craft a pipeline that is a mix of both internal and externally-sourced assets that are in line with the company’s growth goals and strategically fit with both commercial and developmental strengths.

Independent from our therapeutic areas of focus, we’re consciously agnostic of the source of assets that can enrich our global commercial and regional portfolio. The focus is first and foremost on the quality and potential benefit these assets can bring to patients. We consider all opportunities that have the potential to create value using innovative deal structures and creative alliances.

We are particularly interested in opportunities that will support our strategic business areas.


Our R&D groups in Oncology focus on a balanced portfolio of innovative targets as well as more established approaches. These groups are organized around five Innovation Clusters:

  • Oncogenic signaling
  • Antibody-Drug Conjugates
  • DNA Damage & Repair
  • Tumor Metabolism
  • Tumor Plasticity

We actively search and evaluate technologies, preclinical and clinical assets that are able to support and strengthen our Innovation Clusters, and have clear differentiation potential.

Our search space includes antibodies against tumor antigens suitable for antibody-drug conjugation or pro-drug approaches for antibody therapeutics, as well as differentiated bi-specific platform technologies and antibody/protein scaffolds. Selective small molecule assets with well-defined molecular targets that show anti-tumor activity in specific contexts are also a priority, such as those with a proven synthetic lethality relationship in the area of DNA damage and repair, or those controlling tumorigenic metabolic networks in particular cancer genotypes.

In addition to preclinical and clinical assets, we are also interested in biomarker and technology platforms for the advancement of cancer therapies.

Global Business Development (GBD) & External Innovation (EI) work closely together to broaden our access to the world of scientific innovation. Please contact the GBD team in case you are looking for a partner post clinical Proof of Concept. Please contact the EI team for proposal in the pre-clinical and early clinical space up to clinical Proof of Concept.

Brendan Luu

Your Global BD Oncology contact

Lars Weingarten

Your External Innovation Oncology contact


Our focus in Immuno-Oncology is on actively stimulating the immune system, eliminating inhibitory mechanisms and targeting cancer stem cells. The Biopharma Immuno-Oncology strategy is based on four Innovation Clusters:

  • Target “hot” tumors (high level of immune infiltration) and overcome resistance
  • Target tumor myeloid and stromal factors
  • Target “cold” tumors (low level of immune infiltration) to make them “hot”
  • Identify novel resistance pathways

Our search space targeting “hot” tumors includes approaches on T-cell activation and co-stimulation, immune checkpoints beyond PD-1/PD-L1, or metabolic suppression. Profiling of tumor myeloid cells to find novel targets, new ways to inhibit myeloid suppressor cells (MDSC) and enhance macrophage and dendritic cell activity are also of interest to us. New routes to turn “cold” tumors into “hot” tumors may include combination approaches with Antibody-Drug-Conjugate or DNA-repair inhibitors, as well as immunocytokines and T-cell or NK cell re-directed therapies.

In addition to preclinical and clinical assets, we are also interested in biomarker and technology platforms for the advancement of cancer immunotherapies.

Global Business Development (GBD) & External Innovation (EI) work closely together to broaden our access to the world of scientific innovation. Please contact the GBD team in case you are looking for a partner post clinical Proof of Concept. Please contact the EI team for proposal in the pre-clinical and early clinical space up to clinical Proof of Concept.

Send us your proposal for Immuno-Oncology

Brendan Luu

Your Global BD Oncology contact

Christoph Vahl

Your External Innovation Immuno-Oncology contact

Neurology & Immunology

Our focus is the development of best-in-disease therapeutics in autoimmune diseases, with particular interest in Systemic Lupus Erythematosus (SLE), and Lupus Nephritis (LN), inclusive of agents with the potential to reinstate immune tolerance. Additional areas of interest include, Fibrotic disorders (focused on the lung) and disease modifying Osteoarthritis agents, for products with a highly differentiated profile relative to those in the market or undergoing development.

For autoimmune disorders, exemplified by SLE and LN, we are interested in biologics (e.g. monoclonal or bispecific antibodies; fusion proteins, with potential for sub-cutaneous delivery) or orally bioavailable small molecule agents with superior drug-like profiles (e.g. half-life, onset/duration of action, limited undesirable off-target profiles), either in early or late stage development. Our interest also extends to novel targets with strong and differentiated validation and with a well-established preclinical profile, precision medicine/patient stratification approaches and novel drug discovery platform technologies. 

Global Business Development (GBD) & External Innovation (EI) work closely to broaden our access to the world of scientific innovation.

Lori Badura

Your Global BD N&I contact

Eleni Stavridi

Your External Innovation Neurology & Immunology contact


As a world leader in fertility treatment, and aspiring to be an integrated fertility treatment partner we develop and provide innovative products, devices and support services to help infertile couples at every stage of the fertility treatment cycle, from follicular development to early pregnancy.

We actively search and evaluate preclinical and clinical assets and technologies that are able to support and strengthen our aspiration for innovation, and have clear differentiation potential.

Our search space includes innovative developments in the field of IVF, drug assets, IVF lab diagnostics solutions, as well as Artificial Intelligence technologies.

Vincent Attallah

Your Global BD Fertility contact

General Medicine & Endocrinology and regions

Every day, some 60 million patients across the globe use our trusted medicines like Glucophage®; Concor®; Euthyrox® or Saizen® - our brands are amongst the leaders in Emerging Markets in their respective category. Our long-lasting and successful presence in Emerging Markets is based on strong local commercial and medical infrastructure as well as continued investment in our established brands.

We want to fuel additional growth via branded portfolio expansion and meet regional and global commercial needs. We strive to offer patients and physicians products, solutions and services that address unmet medical and patient needs in:

  • Type 2 Diabetes

  • Obesity

  • Cardiovascular Disease
    • Hypertension
    • Cardiac Heart Failure
    • Prevention of MI & Stroke
  • Thyroid Disorders

  • Pediatric Growth Hormone Deficiency

  • Service & digital solutions at Point-of-Care that create value beyond the product

Jan Moeller

Your Global BD GM & Endo and Regions contact

Navin Swaroop

Your APAC Region Business Development contact

Fabio Moreira

Your LATAM Region Business Development contact

Biomarkers & Technologies

We are also looking for innovative biomarker technologies for discovery and clinical application, and for experienced partners to collaborate on worldwide development and commercialization of companion diagnostics for our drug programs.

Global Business Development (GBD) works closely with External Innovation (platform technologies) and Clinical Biomarkers and Diagnostics  to broaden our access to the world of scientific innovation,  Please contact GBD and the respective business representative for your area of interest with your partnering proposals.

Matthias Müllenbeck

Your Global BD Enabling Technologies

Holger Schwarz

Your External Innovation Platform Technology contact

Dennis Merkle

Your EI Clinical Biomarker and Diagnostics contact

Global Health

We have dedicated ourselves to improving access to health in underserved populations with a focus on infectious diseases – especially malaria and schistosomiasis. Here we can contribute the competencies we have acquired from working at the interface of medicines, chemicals and diagnostics.

For most of these diseases, young children are the most vulnerable age group needing a suitable treatment. The goal is to develop innovative and integrated health solutions (drugs, diagnostics, medical devices, vector controls and digital health tools) for the most vulnerable populations in developing countries.

Access to Innovation APAC

As a global science driven pharmaceutical company, we are dedicated to not only research, develop and commercialize its therapeutics worldwide, but also source innovation and collaborate on a global scale. While the technology and therapeutic area specific contacts named above are located either at our Darmstadt headquarters or the Boston R&D site, we have specific Asia Pacific representatives located in Singapore, Shanghai and Tokyo. They are the first point of contact for any partnership proposals from the Asia Pacific region and will facilitate the interaction with the global expert teams.

Birgit Reitmayer

Your BD Access to Innovation APAC contact

Michael Chen

Your External Innovation China contact

Ko Hasegawa

Your External Innovation Japan contact

Alliance Management

Ensuring our alliances are supported by the right teams with the right resources is a priority for us. Our focus is on:

  • Maximizing the value of the alliance for both partners, and reducing the risk of failure
  • Resolving issues in advance in the best interest of the projects
  • Providing a lead alliance governance structure
  • Monitoring whether the legal framework of current alliances still reflect the initial objectives in light of the environmental changes
  • New Opportunities: Identifying new opportunities with current partners

Harm-Jan Borgeld

Your Global Alliance Management contact

External Innovation

With a dedicated team within R&D working closely with Global Business Development, we scout and evaluate external opportunities, including technologies, pre-clinical and early clinical assets in Oncology, Immuno-Oncology, and Immunology across all geographies.

Joern-Peter Halle

Your SVP, Global Head of External Innovation

Martin Picard

Your Global External Innovation Contact


You have accessed, but for users from your part of the world, we originally designed the following web presence

Let's go

Internet Explorer is not supported

You are using an outdated browser. If you would like to use our website, please use Chrome, Firefox, Safari or other browser

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement